Purpose: To compare the efficacy and safety of ranibizumab 0.5 mg versus dexamethasone 0.7 mg according to their European labels in macular oedema secondary to branch retinal vein occlusion (BRVO) in a 6-month, phase IIIb, randomized trial. Methods: Patients received either monthly ranibizumab for 3 months followed by Pro re nata (PRN) treatment (n = 126) or a sustained-release dexamethasone implant followedbyPRN sham injections (n = 118). Mainoutcomes weremeanaveragechange in best-corrected visual acuity(BCVA) from baseline to month1 through month 6, mean changes in BCVA and foveal centre point thickness (FCPT), and adverse events (AEs). Results: There was no difference in BCVA gains between the treatments prior to month 3. Best-corrected visual acuity (BCVA) gain with dexamethasone declined thereafter. From month 3 to month 6, mean BCVA change from baseline was significantly higher with ranibizumab than with dexamethasone [raw means (standard deviation):+16.2 (AE11) letters versus +9.3 (AE10.1) letters]. At month 6, the difference in BCVA gains from baseline was +17.3 letters in the ranibizumab versus +9.2 letters in the dexamethasone group. Patients in the ranibizumab group received a mean of 2.94 loading injections and 1.74 PRN retreatment injections, while those in the dexamethasone group received a single loading injection. Elevated intraocular pressure (IOP) and AEs were more frequent with dexamethasone than ranibizumab treatment. Conclusion: Ranibizumab PRN resulted in greater visual acuity (VA) gains in macular oedema following BRVO compared with single-dose dexamethasone over a 6-month study period, observed from month 3, when administered according to their European label. In clinical practice, retreatment with dexamethasone may be required prior to this point.
Introduction
Macular oedema is the most frequent cause of visual impairment in patients with branch retinal vein occlusion (BRVO) (Bertelsen et al. 2012) . Until recently, grid laser photocoagulation was the standard of care for the treatment of macular oedema due to BRVO in patients with visual acuity (VA) ≤20/ 40 and duration >3 months (BRVO Study Group 1984; Shah et al. 2011; Pielen et al. 2015) . This treatment is known to slow down the progression of vision loss, although its longer-term results are limited and improvement in vision is uncommon (BRVO Study Group 1984; Tan et al. 2014; Pielen et al. 2015) . Treatment of macular oedema secondary to BRVO with antivascular endothelial growth factor (VEGF) agents or corticosteroids has gained widespread acceptance in recent years (Pielen et al. 2013; Szurman et al. 2016) . Indeed, this is reflected in the newly published guidelines (July 2015) on RVO by the Royal College of Ophthalmologists. Ranibizumab (LucentisÒ; Novartis Pharma AG, Basel, Switzerland, and Genentech Inc., South San Francisco, CA, USA) and the dexamethasone intravitreal implant (OZURDEXÒ; Allergan Inc., Irvine, CA, USA) are among the recommended first-line treatments in the UK, Europe and USA (Pielen et al. 2013; Sivaprasad et al. 2015) .
Ranibizumab is a humanized monoclonal antibody fragment (Fab) lacking the Fc domain that selectively binds to and inhibits all active isoforms of VEGF-A (Ferrara et al. 2006 ). Ranibizumab 0.5 mg was approved in June 2010 by the United States Food and Drug Administration (US FDA) and by the European Union (EU) in June 2011 for the treatment of visual impairment due to macular oedema secondary to BRVO. The approval of ranibizumab was based on the 6-month results of a phase III randomized double-masked controlled study 'BRAnch retinal Vein Occlusion: Evaluation of Efficacy and Safety trial' (BRAVO) (Campochiaro et al. 2010) . Subsequent extension studies, HORI-ZON and RETAIN, established the long-term safety and efficacy of ranibizumab 0.5 mg over a period of 2 years, with no new safety concerns and maintenance of stable VA in patients with BRVO (Heier et al. 2012; Campochiaro et al. 2014) .
The dexamethasone intravitreal implant, a potent, water-soluble, biodegradable corticosteroid that is delivered into the vitreous cavity, provides an alternative method of treating macular oedema secondary to BRVO (Higham et al. 2016) . Dexamethasone intravitreal implant was approved in June 2009 by the US FDA for the treatment of macular oedema secondary to BRVO based on the 6-month results of a phase III shamcontrolled study 'Global Evaluation of implaNtable dExamethasone in retinal Vein occlusion with macular edemA' (GENEVA) (Haller et al. 2010) . Theoretically, the dexamethasone intravitreal implant provides sustained release of the corticosteroid for a number of months following a single injection. However, limitations in the design of the GENEVA study, such as the enrolment of both BRVO and central retinal vein occlusion (CRVO) patients and the collection of limited data between months 3 and 6, made it difficult to determine the duration of effect of the implant and, therefore, to determine the optimal retreatment interval. To date, several investigators have suggested that retreatment with dexamethasone intravitreal implant may be required after 4-6 months (Bezatis et al. 2013; Guignier et al. 2013; Querques et al. 2013; Kim et al. 2015; Rezar-Dreindl et al. 2016) . However, the results of these studies have not been conclusive due to their retrospective nature or small sample size. Subsequent 12-month data of the GENEVA trial also revealed that repeated dexamethasone intravitreal implant applications were associated with steroid-related complications such as elevated intraocular pressure (IOP) and cataract (Haller et al. 2011) .
Despite the limitations associated with the GENEVA study, the European Committee for Medicinal Products for Human Use (CHMP) licensed the dexamethasone intravitreal implant for 6-monthly use based on data from this study. The dexamethasone intravitreal implant label states that, following initial intravitreal injection, retreatment may be performed after approximately 6 months if the patient experiences decreased vision and/or an increase in retinal thickness.
Several prospective and retrospective clinical studies have evaluated ranibizumab and dexamethasone intravitreal implant as treatments for BRVO (Campochiaro et al. 2010 (Campochiaro et al. , 2014 Haller et al. 2010 Haller et al. , 2011 Heier et al. 2012 ). To date, there have been no prospective randomized trials comparing the efficacy or duration of effect of both approved treatment options. The COMRADE-B study is the first head-to-head phase IIIb study designed to compare the efficacy and safety of intravitreal ranibizumab 0.5 mg injection PRN versus a single injection of the 0.7 mg dexamethasone intravitreal implant in patients with vision loss resulting from macular oedema secondary to BRVO. Owing to the head-to-head nature of this European study, it was necessary that treatment was carried out according to the EU Summary of Product Characteristics (SmPC) for ranibizumab and dexamethasone intravitreal implant (EMA/ SmPC 2013 .
Materials and Methods

Study design
The COMRADE-B study was a 6-month, phase IIIb, multicentre, randomized, double-masked study that enrolled 244 patients with visual impairment due to macular oedema secondary to BRVO. Patients were enrolled from 74 sites across Germany, Great Britain, the Czech Republic, Poland and Hungary. The study was conducted between July 2011 and June 2013 in accordance with the International Conference on Harmonization, Harmonized Tripartite Guidelines for Good Clinical Practice, with the applicable local regulations, and the Declaration of Helsinki. The study protocol was reviewed and approved by an independent ethics committee or an institutional review board or a research ethics board for each contributing centre. Patients provided written informed consent before entering the study. The COMRADE-B study is registered on clinialtrials.gov as NCT01396057.
Patients
The study population consisted of male and female patients ≥18 years of age. Inclusion criteria were diagnosis of visual impairment due to macular oedema secondary to BRVO at maximum 6 months prior to screening and best-corrected visual acuity (BCVA; study eye) of 20/ 40 (6/12 m) to 20/400 (6/120 m) using Early Treatment Diabetic Retinopathy Study (ETDRS)-like VA testing charts. Key exclusion criteria were (i) history of (a) radial optic neurotomy or sheathotomy in the study eye, (b) the presence of either dry or wet age-related macular degeneration in the study eye, (c) hypersensitivity to any of the study drugs or to drugs with similar chemical structures, (d) allergy to fluorescein; (ii) central subfield retinal thickness (CSRT) <250 lm in the study eye; (iii) prior episodes of RVO in the study eye; (iv) anti-VEGF treatment in the study eye or the fellow eye within 3 months prior to baseline; (v) panretinal scatter photocoagulation or sector laser photocoagulation performed within 3 months before baseline or anticipated to be performed in the 4 months following randomization; (vi) use of intraocular corticosteroid within 6 months before baseline; (vii) IOP of ≥30 mmHg or uncontrolled glaucoma; patients could be rescreened after 1 month if they had undergone glaucoma treatment; and (viii) a history of cerebral vascular accident or myocardial infarction within 12 months prior to baseline.
Randomization and treatment
A randomization list was produced using a validated system that randomly assigned the treatment arms to randomization numbers in the specified ratio ( Fig. 1) . At enrolment, patients were randomized 1:1 to receive either ranibizumab or dexamethasone intravitreal implant treatment. For all patients, one eye was selected and treated as the study eye. If both the eyes were eligible, then the eye with the worse VA (assessed at visit 1) was selected, unless the investigator deemed that the fellow eye was more appropriate for study treatment. All patients received treatment in accordance with the European Union SmPC for ranibizumab (EMA/SmPC 2013) or dexamethasone intravitreal implant (EMA/SmPC 2015). As mandated by the study protocol, no adjustments of the ranibizumab or dexamethasone intravitreal implant dosing regimen or rescue therapy were allowed.
Ranibizumab group
Patients received ranibizumab 0.5 mg injections as per the EMA/SmPC (2013), that is a minimum of three initial consecutive monthly ranibizumab injections at the start of the study until a stable VA was reached (defined as stable or no change in VA for three consecutive monthly assessments), followed by PRN treatment (EMA/SmPC 2013). Thereafter, patients were monitored monthly for VA. Monthly treatment was resumed if there was a loss of VA due to disease activity, and was continued until stable VA was reached again for three consecutive monthly assessments (Fig. S1 ).
Dexamethasone group
Patients received a single sustainedrelease intravitreal 0.7 mg dexamethasone intravitreal implant as per the EU SmPC at baseline (EMA/SmPC 2015). Thereafter, they received monthly sham injections until month 3 followed by a PRN regimen. The sham injections consisted of empty sterile syringes without needles, and the procedure involved applying pressure against the globe of the eye to mimic the injection procedure of the ranibizumab group (Fig. S1 ).
Masking and randomization A minimum of two investigators were involved, per study site, to fulfil the masking requirements. All ocular assessments were carried out by the evaluating physician who was masked to the treatment assignment. The injecting physician was unmasked and performed the study drug administrations as per the protocol; however, they were not involved in any other aspects of the study and were not allowed to communicate the details of the treatment to anyone.
Study objectives
The primary objective was to compare the response to treatment with ranibizumab compared with dexamethasone intravitreal implant over 6 months. This was assessed by the mean average change in BCVA from baseline to month 1 through month 6. The secondary objectives were (i) to compare the efficacy of ranibizumab versus dexamethasone intravitreal implant for (a) mean change in BCVA and CSRT at month 6, (b) proportion of patients with a BCVA gain or loss of ≥15/≥10/≥5 letters at month 6, (c) time to achieve a significant improvement in BCVA, defined as ≥15 letters; (ii) to compare increase rate in IOP from baseline to month 6 with ranibizumab treatment compared to dexamethasone intravitreal implant.
Efficacy and safety assessments
Best-corrected visual acuity The BCVA of the study eye was assessed at every visit using an ETDRS-like VA testing chart at a testing distance of 4 m. The primary end-point was the mean average change in BCVA from baseline to month 1 through month 6, which is the mean difference of BCVA versus baseline over all monthly postbaseline assessments from month 1 to month 6. This endpoint provides a more robust estimate as it accounts for both interpatient and intramonth variability in BCVA than a mean change assessed at a single timepoint (month 6, which is the end of the study). Secondary end-points included mean change in BCVA from baseline to month 6, proportion of patients gaining ≥15/≥10/≥5 letters at month 6, proportion of patients losing ≥15/≥10/≥5 letters at month 6 and time to achieve a significant improvement of ≥15 letters.
Colour fundus photography and fluorescein angiography Colour fundus photography in conjunction with fluorescein angiography (FA) was conducted at screening and at the end of the study. Colour fundus photography and FA images were independently reviewed by the central reading centre (CRC) at University of Bonn, Germany, to ensure standardized evaluation. Additional assessments (study eye) for retreatment were carried out, as needed from baseline to month 5.
Optical coherence tomography
Optical coherence tomography (OCT) was performed by certified site personnel at all visits using spectral domain optical coherence tomography (SD-OCT) equipment. If SD-OCT was not available, then stratus time domain OCT was used; it was ensured that the same OCT system was used per patient throughout the study period. Images were taken using a standard photography protocol, and these were then processed in the CRC under standard procedures. Retinal thickness was assessed in terms of CSRT and foveal centre point thickness (FCPT; by the CRC, University of Bonn, Bonn, Germany).
Treatment exposure
The number of injections (ranibizumab or sham) given to the ranibizumab or dexamethasone intravitreal implant group was evaluated over a period of 6 months.
Safety assessments Safety was assessed by the incidence of treatment-emergent adverse events (AEs) and treatment-emergent serious AEs (SAEs), by ophthalmic examinations, evaluation of cataract formation, rate of patients with ≥10% increase in IOP, changes in vital signs (blood pressure and heart rate) and laboratory evaluation results (haematology panel, biochemistry panel, urinalysis panel), over the 6-month study period/assessment period. All ocular/non-ocular AEs and SAEs were recorded, including information on their relationship to the study drug and/or ocular injection procedure. All AEs were summarized by the proportion of patients experiencing AEs, based on the standardized Medical Dictionary for Regulatory Activities by system organ class and preferred term.
Study withdrawal and study drug discontinuation
At the discretion of the investigator, patients deemed to have an unsatisfactory therapeutic effect or recurrence prior to completion of the trial discontinued study treatment and received therapy as needed. Treatment failure was defined by the following criteria: the absence of visual improvement at visits 5, 6 and 7 compared to baseline BCVA at visit 1 and improvement of central retinal thickness ≤10% (250 lm ≤ CRTbaseline ≤ 500 lm) or 50 lm (CRTbaseline ≥500 lm) compared to baseline CRT (CRTbaseline) at visit 1 or decrease in BCVA ≥30 letters in the study eye compared with last assessment of BCVA prior to most recent treatment. Patients were also withdrawn from the study at any time if the investigator concluded that participation in the trial would put the patient's safety at risk or withdrawal would be in the patient's best interests.
Conditions requiring discontinuation from treatment included rhegmatogenous retinal detachment, development of macular hole stage III-IV, transient ischaemic attack or stroke. Criteria for study drug (ranibizumab and dexamethasone intravitreal implant) interruption until the condition resolved or had been treated successfully included intraocular inflammation, elevated IOP in the study eye ≥30 mmHg, occurrence of retinal break in the study eye, and ocular or periocular infection or intraocular surgery in the study eye within the previous 28 days.
Statistical analysis
A sample size of 108 patients in each of the treatment groups was considered to have 90% power to detect a significant difference on a two-sided, 5% significance level, if the true difference was six letters with a common standard deviation (SD) of 13.5. To compensate for dropouts and other protocol violations, 120 patients were considered in each of the treatment groups.
The randomized set consisted of all patients who were randomized to one of the treatment groups. Patients were considered randomized when they were allocated a randomization number. The full analysis set (FAS) consisted of all randomized patients who had received at least one application of the study treatment and had at least one postbaseline assessment for BCVA.
Primary analysis was performed using the FAS with a last observation carried forward (LOCF) approach for imputing missing data and using the analysis of covariance model with average change in BCVA (ETDRS letters) from baseline to month 1 through month 6 as a dependent variable. The primary end-point variable was the average of the changes in BCVA letter score from baseline to any postbaseline assessment from month 1 to month 6. Raw means, SD and least-square (LS) means with corresponding 95% confidence intervals (CI) and p-values were calculated as point estimates for the treatment contrasts. The null hypothesis stated that 'there is no difference in the change of BCVA averaged over all postbaseline visits'.
Sensitivity analysis of the primary analysis was conducted within the FAS by comparing the primary analysis (based on LOCF) versus the 'as-observed' approach, which used only the observed values without imputation for missing values. Further sensitivity analysis was performed using a mixed model for repeated measures. Time to BCVA gain of ≥15 letters was analysed using the Kaplan-Meier method.
Safety analysis was performed on the safety set that consisted of all randomized patients who had received ≥1 application of the study treatment and had ≥1 postbaseline safety assessment. Patients who had not experienced any AEs were also included.
Descriptive statistics were provided for patient demographics and all baseline characteristics, and study treatment exposure, and these included sample size (n), mean, SD, median and a range for continuous variables, frequencies and percentages for categorical variables.
Results
Patients and baseline characteristics
Of the 337 patients screened, 244 were randomized (1:1) either to ranibizumab (n = 126) or dexamethasone intravitreal implant (n = 118). Overall, 215 (88.1%) patients completed this 6-month study. A greater proportion of the dexamethasone intravitreal implant group discontinued their participation in the study compared with the ranibizumab group (15.3% versus 8.7%). Reasons for discontinuation in both groups included AEs, unsatisfactory therapeutic effect and protocol deviations (eight patients each, 3.3%; Fig. 1 ; including seven patients in the ranibizumab group who received only two monthly injections). The proportion of patients who discontinued the study because of unsatisfactory therapeutic effect was higher in the dexamethasone intravitreal implant group compared with ranibizumab (5.1% versus 1.6%).
The efficacy and safety analyses were performed on the FAS and the safety set, respectively, both consisting of 126 ranibizumab-treated and 118 dexamethasone intravitreal implant-treated patients.
Overall, patient demographic and baseline ocular characteristics were similar between the two treatment groups as displayed in Table 1 . At baseline, 92.2% of the patients had active concomitant medical conditions, the most common being hypertension (65.6%), hypercholesterolaemia (18.9%) and cataract (6.1%). The number of patients who had previous cataract surgery was 6 (4.8%) in the ranibizumab group and 7 (5.9%) in the dexamethasone group. Of 126 BRVO patients enrolled in this study, 44 (34.9%) in the ranibizumab group and 37 (31.4%) in the dexamethasone group had retinal ischaemia at baseline. After 6 months, retinal ischaemia was observed in 42 (33.3%) patients who had been treated with ranibizumab, compared to 50 (42.4%) in the dexamethasone group.
Efficacy
Best-corrected visual acuity There was no difference in BCVA between PRN ranibizumab and dexamethasone intravitreal implant at months 1 and 2, suggesting similar initial efficacy. However, a difference in BCVA outcome between ranibizumab and dexamethasone intravitreal implant was evident from month 3, mean change in BCVA from baseline being significantly higher with ranibizumab than dexamethasone intravitreal implant [raw means (SD): +16.2 (AE11) letters versus +9.3 (AE10.1) letters]. Best-corrected visual acuity gain with dexamethasone intravitreal implant declined thereafter, whereas the improvement in mean BCVA was maintained for the 6-month study duration with ranibizumab PRN [change from baseline at month 6, raw means (SD): +17.3 (AE11.8) letters versus +9.2 (AE12.5) letters; Fig. 2 ]. Mean (AESD) average change in BCVA from baseline to month 1 through month 6 was +14.9 (AE9.86) letters (LS-baseline-adjusted means 14.2 letters) for ranibizumab and +10.1 (AE9.51) letters (LS-baselineadjusted means 9.7 letters) for the dexamethasone intravitreal implant (Fig. 3) .
A sensitivity analysis performed using the 'as-documented' approach (observed values only, without imputation) confirmed the results observed with the primary analysis (FAS, LOCF approach, data not shown), showing the robustness of the primary analysis regarding missing values. At month 6, a greater proportion of patients gained ≥15 letters with ranibizumab (61.1%) as compared with dexamethasone intravitreal implant (37.3%; Fig. 4) . Similarly, patients with a ≥10 and ≥5 letter gain were numerically higher with ranibizumab (77% and 85.7%) compared with dexamethasone intravitreal implant (53.4% and 64.4%; Fig. 4) . Data for the proportion of patients with ≥15, ≥10 and ≥5 letters loss are presented in Fig. S2 .
Time to achieve significant improvement of ≥15 letters: More patients in the ranibizumab group (73.9%) achieved a significant ≥15 letter improvement in BCVA at month 6 from baseline compared to those in the dexamethasone intravitreal implant group (63.7%) as estimated by Kaplan-Meier analysis. The median time to event (i.e. the time when half of the patients achieved the respective improvement) was similar for both treatment groups (63 days with dexamethasone intravitreal implant versus 64 days with ranibizumab), whereas the estimated rate for month 6 was higher with ranibizumab.
Anatomical outcomes
Both drugs were effective in reducing FCPT initially, with a rapid and substantial reduction in FCPT observed as early as month 1 after treatment initiation. While the ranibizumab group maintained this reduction in FCPT over time, the mean FCPT increased from month 3 onwards in the dexamethasone intravitreal implant group. Therefore, from baseline to month 6, there was a significantly higher decrease in the mean (AESD) FCPT with ranibizumab compared with dexamethasone intravitreal implant [274.6 (AE210) lm versus 129.5 (AE211) lm; p < 0.001]. These findings were in accordance with the results observed for the mean change in CSRT [mean (AESD): À230.6 (AE169.3) lm with ranibizumab; À112.3 (AE172.1) lm with dexamethasone intravitreal implant; Fig. 5 ]. At baseline, 66 (54%) patients in the ranibizumab group exhibited serous retinal detachment in the macular area, compared to 54 (46.2%) in the dexamethasone group. By the end of the follow-up, accumulation of subretinal fluid was observed in 12 (10.3%) eyes that had been treated with ranibizumab and in 24 (24.2%) dexamethasone-treated eyes.
The use of SD-OCT was equally distributed in both treatment groups. Overall, seven patients (5.6%) in the ranibizumab group and 8 (6.8%) in the dexamethasone group were examined by standard OCT.
Treatment exposure
The majority of patients (94.4%) treated with ranibizumab received three initial monthly ranibizumab injections, as mandated by the protocol. During the PRN retreatment period, patients received a mean of 1.76 ranibizumab and 1.82 sham injections. Overall, patients treated with ranibizumab received a mean of 4.71 injections, including the three initial monthly protocol-mandated injections. Patients in the dexamethasone group received a single dexamethasone 
Safety
Treatment-emergent serious adverse events Ocular SAEs were reported in two patients (conjunctivitis, ocular hypertension and cellulitis) treated with dexamethasone intravitreal implant. There were no deaths reported in either of the treatment groups during the study. No ocular SAEs were suspected to be related to the study drug. Non-ocular SAEs were reported in 7 (5.6%) patients treated with ranibizumab and 8 (6.8%; one related to the injection procedure and led to treatment discontinuation) patients who received dexamethasone intravitreal implant. None of the nonocular SAEs was suspected to be related to the study drug (Table S1 ).
Treatment-emergent adverse events (study eye) Treatment-emergent ocular AEs were reported in 61 (48.4%) and 74 (62.7%) patients treated with ranibizumab and dexamethasone intravitreal implant, respectively, as displayed in Table S2 . Treatment-emergent ocular AEs suspected to be related to the study drug or treatment procedure are summarized in Table S3 . Cataract formation was observed in one ranibizumab-treated patient, compared to four patients who received dexamethasone.
Mean intraocular pressure
Over the 6-month treatment period, the mean IOP was stable for patients treated with ranibizumab (range 14.9 AE 2.6 to 15.7 AE 2.8). Mean IOP at baseline and month 6 in the ranibizumab group was 15.2 AE 2.7 mmHg and 15.5 AE 3.2 mmHg, respectively. In contrast, the mean IOP at baseline in the dexamethasone intravitreal implant group was 15.3 AE 2.6 mmHg, which then increased to 20.2 AE 6.1 mmHg at month 2 and subsequently decreased to a mean of 15.9 AE 3.1 mmHg at month 6, reflecting the diminishing ocular pharmacological activity of the steroid implant (Fig. 6 ). 
Discussion
The COMRADE-B study is the first prospective randomized study directly comparing ranibizumab and dexamethasone intravitreal implant treatment according to their European labels in patients with macular oedema secondary to BRVO over a 6-month period. The biodegradable dexamethasone intravitreal implant was designed for the long-term treatment of macular oedema in RVO, with the theoretical advantage of sustained release of dexamethasone intravitreal implant over months following a single intravitreal injection. The European Union Summary of Product Characteristics for dexamethasone intravitreal implant, which formed the basis for the treatment protocol in the present study, recommends retreatment only after a period of 6 months following initial injection (EMA/SmPC 2015). However, in the GENEVA trial, a duration of action of dexamethasone intravitreal Consists of all randomized patients who received at least one application of the study treatment and had at least one post-baseline assessment for BCVA. BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study.
implant of less than 6 months was observed, with no further increases in BCVA following the month 2 injection (Haller et al. 2010) . To date, the optimal retreatment interval for dexamethasone intravitreal implant in the management of RVO remains controversial. Several studies have indicated that repeated injection with dexamethasone may be required after 4-6 months (Bezatis et al. 2013; Guignier et al. 2013; Querques et al. 2013; Kim et al. 2015) . Recently, Kim et al. (2015) reported that intravitreal anti-VEGF treatment administered PRN monthly and dexamethasone intravitreal implant administered PRN at 6-month intervals may yield functionally and anatomically comparable results at 12 months. Querques and coworkers found that eyes with macular oedema secondary to retinal vein occlusion required retreatment with intravitreal dexamethasone implant after 4.7 AE 1.1 months from the first and 5.1 AE 1.5 months from the second injection (Querques et al. 2013 ). An additional investigation observed no significant difference between an anti-VEGF and dexamethasone intravitreal implant PRN treatment regimen after 6 months (Guignier et al. 2013) . In this study, 10 of 11 eyes required repeat doses of dexamethasone intravitreal implant after 4 months of follow-up (Guignier et al. 2013 ). The results of these studies, however, have not been very conclusive due to their retrospective nature or small sample size. Other recent studies have investigated the use of dexamethasone intravitreal implant at intervals shorter than 6 months (Gado & Macky 2014; Maturi et al. 2014; Higham et al. 2016) , with Gado et al. suggesting a retreatment with dexamethasone at approximately 4 months after the initial first treatment (Gado & Macky 2014) .
In our study, treatment with three initial monthly ranibizumab 0.5 mg injections followed by a PRN dosing regimen resulted in significantly better VA outcomes than treatment with sustained-release intravitreal dexamethasone implant, administered once at baseline, with sham injections thereafter. While both therapies provided similar efficacy up until month 2, significant differences in BCVA between ranibizumab and dexamethasone intravitreal implant were evident from month 3 of treatment. Best-corrected visual acuity gain with dexamethasone intravitreal implant declined thereafter, whereas the improvement in mean BCVA was maintained for the 6-month study duration with ranibizumab PRN. The proportion of patients who achieved a significant improvement in BCVA, defined as ≥15 letters gain, was higher with ranibizumab than with dexamethasone intravitreal implant between months 1 and 6. Improvements in mean BCVA were accompanied by a statistically significant reduction in mean FCPT in ranibizumab-treated patients between months 1 and 6.
Our findings are consistent with several previous non-randomized case series demonstrating that dexamethasone intravitreal implant reinjection is required around 3 months after initial treatment (Mayer et al. 2013 ). Mayer et al. assessed the efficacy of a single injection of dexamethasone intravitreal implant in eyes with macular oedema and BRVO (n = 16) or CRVO (n = 22). Recurrence of macular oedema was observed 3.5 months after initial injection of dexamethasone intravitreal implant among eyes with BRVO and 3.8 months in those with CRVO (Mayer et al. 2013) . In a case series, Giudice et al. (2012) reported that the peak effects of dexamethasone intravitreal implant were observed 2 months after administration, with a substantial dropoff between 2 and 3 months in eyes with macular oedema due to BRVO (n = 7) or CRVO (n = 8). These data suggest that sustained drug delivery implant patients need repeat treatment much earlier than is indicated by the EU label (Giudice et al. 2012) .
In our study, treatment with dexamethasone intravitreal implant was associated with a relatively high dropout rate of 18 patients (15.3%), mostly related to AEs, unsatisfactory therapeutic effect according to prespecified criteria or protocol deviations. The most frequent protocol violations were postbaseline visit missing, missing a study injection and patient not withdrawn after treatment failure. Most patients (n = 8) withdrew from the study 4 months after receiving dexamethasone intravitreal implant because of an unsatisfactory therapeutic effect. The BCVA data from our study suggest that at 4 months after injection, the therapeutic effect of dexamethasone intravitreal implant would be somewhat limited compared with months 1-3. The high rate of discontinuation at this time is, therefore, unsurprising and indicates that retreatment with dexamethasone intravitreal implant should occur around month 3. The current findings are in accordance with those reported in pivotal studies of ranibizumab and dexamethasone intravitreal implant in BRVO. The BRAVO study reported that patients with monthly ranibizumab 0.5 mg experienced a mean BCVA change of +18.3 letters at month 6, which is numerically higher than the mean BCVA gained in the COMRADE-B study (+17.3 letters) (Campochiaro et al. 2010 ). This small difference of one letter may be partly explained by the differences in the ranibizumab treatment regimen between the two studies. The BRAVO study mandated monthly ranibizumab injections, whereas the COMRADE-B study mandated three initial monthly ranibizumab injections, followed by PRN. Thus, patients received an average of 5.7 ranibizumab injections in the BRAVO study, versus 4.76 in the COMRADE-B study. In addition, baseline mean BCVA was numerically lower in the BRAVO (53.0 letters) study than the COMRADE-B study (57.5 letters), and patients in the BRAVO study were allowed to receive rescue grid laser treatment which was not allowed in this study. Despite differences in study design and baseline demographics, the overall percentage of patients achieving ≥15 letter gain was similar in both studies (~60%) (Campochiaro et al. 2010) . However, caution needs to be exercised when interpreting results and making cross-trial comparisons due to differences in baseline characteristics, inclusion and exclusion criteria, treatment regimen and study design.
In the GENEVA study, patients received a single 0.7 mg dexamethasone intravitreal implant in the 6-month study period. Mean BCVA improved by less than 10 letters at month 2 from baseline and declined progressively until the end of 6 months (%five letters). This observation corresponds well with the current findings. However, in the GEN-EVA study, the proportion of patients achieving a ≥ 15 letter gain at month 6 was numerically lower than in the current study (22% versus 37.3%) (Haller et al. 2010) .
Improvements in BCVA were paralleled by a significant reduction in mean FCPT from baseline with ranibizumab compared to dexamethasone intravitreal implant (274.6 lm versus 129.5 lm; p < 0.001). In addition, reduction in FCPT was observed as early as month 1 after treatment initiation in both groups and was maintained in the ranibizumab group for the study duration. However, in the dexamethasone group, mean FCPT increased over time despite the initial observed reduction. These observations were consistent with those reported in the BRAVO and GENEVA studies (Campochiaro et al. 2010; Haller et al. 2010 ). More importantly, the absolute reduction in FCPT with ranibizumab treatment was similar to the upper limit of normal FCPT (%275 lm).
No new safety concerns were identified with ranibizumab or dexamethasone intravitreal implant treatment in this study (Abdolrahimzadeh et al. 2016) . Overall, the incidences of ocular and non-ocular AEs were higher with dexamethasone than with ranibizumab treatment. A greater number of patients dropped out from the dexamethasone intravitreal implant group than the ranibizumab group because of AEs or unsatisfactory treatment. Adverse events that led to study discontinuation with dexamethasone intravitreal implant were mainly related to reduced VA and macular oedema at visits 5, 6 and 7. There were no deaths or cases of endophthalmitis reported in the study, and no cases of ocular SAEs with ranibizumab treatment (Grzybowski 2015; Ng et al. 2015) . Of the four cases of glaucoma suspected to be related to the study drug, three were reported with dexamethasone intravitreal implant treatment (Kim et al. 2014; Aref et al. 2015) . Cataract progression was reported in one patient in the ranibizumab group and in four patients who received dexamethasone. The observed differences in incidence rates of AEs are likely to be attributed to the study drugs. Notably, more patients in the dexamethasone intravitreal implant group reported a ≥10% increase in IOP, which is a well-known risk with corticosteroids (Aref et al. 2015) . Intraocular pressure change with dexamethasone treatment was highest at month 2 and decreased thereafter, reflecting the ocular pharmacological activity of the corticosteroid and use of topical IOP-lowering medication. This observation was consistent with that of the GENEVA study (Haller et al. 2010) . At the same time, mean BCVA gain with dexamethasone intravitreal implant (+13.4 letters) at month 2 also decreased from month 3 until the end of the study.
A potential limitation of the present study was that dexamethasone intravitreal implant was administered just once during the 6-month study period according to the EU SmPC. In the light of a significantly better clinical outcome with ranibizumab PRN as early as 3 months after the initial treatment, a dexamethasone PRN regimen may have provided a more robust comparison between the two treatment groups.
Results of the COMRADE-B study show that, when administered according to their European labels, ranibizumab PRN results in visual acuity gains which are significantly higher than those achieved with a single injection of dexamethasone intravitreal implant in patients with macular oedema secondary to BRVO from month 3 of a 6-month study. Moreover, ranibizumab was demonstrated to be safer than dexamethasone with regard to ocular AEs, including IOP increase and cataract progression.
Some questions remain unanswered, particularly the long-term outcomes of continued treatment with ranibizumab and dexamethasone intravitreal implant based on prespecified PRN retreatment criteria (Bertelmann et al. 2016) , and the number of injections required to achieve optimal outcomes and disease resolution. Of note, lowering the number of ranibizumab injections while maintaining efficacy remains an unmet need in BRVO. Efforts should be made to address this treatment burden in the future. Currently, a phase IV study comparing the efficacy and safety of ranibizumab and dexamethasone intravitreal implant in patients with macular oedema secondary to BRVO over 12 months is ongoing, which will address some of these questions (COMRADEExtension, NCT01580020).
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Additional Supporting Information may be found in the online version of this article: Figure S1 . Treatment schedule. Figure S2 . Categorized BCVA loss at month 6 [full analysis set (last observation carried forward)]. Table S1 . Treatment emergent ocular (study eye) and non-ocular (>1% patients in any group) serious adverse events from baseline to month 6, regardless of the study drug relationship (safety set*). Table S2 . Most frequent treatmentemergent ocular (study eye) and nonocular adverse events (>3% of patients in any group) from baseline to month 6, regardless of the study drug relationship (safety set*). Table S3 . Treatment emergent ocular (study eye) and non-ocular adverse events from baseline to month 6, suspected to be related to the study drug (safety set*). Data S1. Study funding and affiliations.
